Ixico (IXI)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

12.00p
   
  • Change Today:
      0.25p
  • 52 Week High: 12.75
  • 52 Week Low: 6.45
  • Currency: UK Pounds
  • Shares Issued: 92.67m
  • Volume: 40,258
  • Market Cap: £11.12m
  • Beta: 0.01

Ixico reports progress in Huntington's disease imaging consortium

By Josh White

Date: Monday 29 Jul 2024

LONDON (ShareCast) - (Sharecast News) - Medical imaging analytics specialist Ixico reported significant progress in its Huntington's disease imaging harmonisation (HD-IH) consortium on Monday.
The AIM-traded firm said that in June, an additional bio-pharma partner joined the consortium, which originally included the CHDI Foundation, uniQure, PTC Therapeutics, and Asklepios BioPharmaceutical.

Using Ixico's AI-powered IXIQ.Ai platform, the consortium had analysed more than 6,000 MRI scans, generating data that supports using imaging biomarkers as clinical trial endpoints.

Preliminary findings presented by Dr Marina Papoutsi at the February HD-TC conference demonstrated the potential of brain volume changes as surrogate trial endpoints.

HD-IH was continuing to seek new partners to expand its biomarker development programme, aiming to enhance the precision and efficacy of clinical trials for Huntington's disease.

"We are delighted with the progress made in the HD-IH consortium over the past year," said chief scientific officer Dr Robin Wolz.

"The results presented at the HD-TC conference show how the initial data generated via this partnership provides additional evidence of the impact that MRI-based biomarkers have in HD clinical development."

Dr Wolz said the further expansion in the number of HD-IH biopharmaceutical partners demonstrated the value the collaboration provided to the industry.

"By completing the analysis of the available data over the remainder of 2024 and focusing on the resulting biomarker evidence, the consortium will provide unique scientific understanding and insights for successful operational implementation of those measurements in clinical development."

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Ixico Market Data

Currency UK Pounds
Share Price 12.00p
Change Today 0.25p
% Change 2.13 %
52 Week High 12.75
52 Week Low 6.45
Volume 40,258
Shares Issued 92.67m
Market Cap £11.12m
Beta 0.01

Ixico Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
23.37% below the market average23.37% below the market average23.37% below the market average23.37% below the market average23.37% below the market average
57.45% above the sector average57.45% above the sector average57.45% above the sector average57.45% above the sector average57.45% above the sector average
Price Trend
2.82% above the market average2.82% above the market average2.82% above the market average2.82% above the market average2.82% above the market average
44.68% above the sector average44.68% above the sector average44.68% above the sector average44.68% above the sector average44.68% above the sector average
Income Not Available
Growth
79.86% below the market average79.86% below the market average79.86% below the market average79.86% below the market average79.86% below the market average
87.1% below the sector average87.1% below the sector average87.1% below the sector average87.1% below the sector average87.1% below the sector average

Ixico Dividends

No dividends found

Trades for 28-May-2025

Time Volume / Share Price
12:10 40 @ 12.48p
08:20 218 @ 11.53p
08:15 40,000 @ 11.63p

Ixico Key Personnel

CEO Giulio Cerroni
CEO Bram Goorden

Top of Page